Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Abrupt discontinuation can cause rebound appetite and metabolic changes
Expert Opinion from Dr
While all GLP-1 agonists work in a similar way and come with similar side effects, there are key differences in how theyre formulated, used, and what theyre approved for
[11] [12] mhra.gov.uk)
A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
